Singapore: Japan-based Pharma Takeda has increased its efforts for strategic investments in Israel through its Silicon Valley-based venture fund, Takeda Venture Investments (TVI) on Thursday.

"In Israel, I think there is an exceptional set of conditions that make it a great place for a company like us to invest in innovation," said Mr Tetsuyuki Maruyama, head of the R&D team.

To market its pharmaceutical products, in 2013 Takeda launched a commercial subsidiary in Israel, and in the following year it has helped establish a biotechnology accelerator, FutuRx, with the help of Johnson & Johnson Innovation and OrbiMed Israel Partners.

The four companies which focus generally on biotechnology, have gone through FutuRx. According to Mr Michal Silverberg, TVI's senior director of External Innovation, Takeda is looking forward to fund new companies which fit in with the suitable strategic vision through TVI and is currently doing its diligence on several other promising aspects in Israel.

In Israel, the expansion is a part of the recent change in the company's strategy, which has pushed it towards more global engagement.

"Our external or collaborative innovation strategy is to grow rapidly in Takeda, and I think we have realized that in order to succeed in the changing pharma market, we have to look outside the four walls to find more innovations, and even outside the traditional places where we work," said Mr Maruyama.

The company looks forward to greater personalization of medicine in the future particularly but, the vast technological conflicts are pushing the company to look into a variety of fields.